Milestone Scientific (MLSS) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
18 Sep, 2026Company overview and business model
Incorporated in Delaware with principal offices in Roseland, New Jersey, focusing on scientific and technological innovation.
Offering details and pricing
Registration statement filed for the issuance and sale of up to $45,000,000 in securities, including common stock, preferred stock, warrants, rights, and units.
Securities may be offered from time to time on a delayed or continuous basis under Rule 415.
The offering structure allows for various combinations of securities, with terms to be set in future prospectus supplements.
Management team and governance
CEO and principal executive officer is Eric Hines; other key officers include Keisha Harcum (VP of Finance and Acting Chief Accounting Officer) and Benedetta Casamento (Chairman of the Board).
Board includes multiple directors, with signatures provided for compliance.
Latest events from Milestone Scientific
- Registering up to $45M in securities to fund growth and commercialization of patented injection technologies.MLSS
Registration filing - Q2 revenue up 22%, medical sales soared 231%, but cash constraints raise going concern risk.MLSS
Q2 2026 - All proposals passed, reinforcing growth focus and executive alignment with performance goals.MLSS
AGM 2026 - Shareholders will vote on director elections, equity plan expansion, and key governance proposals.MLSS
Proxy filing - Virtual meeting to vote on directors, share increases, equity plan, pay, and auditor ratification.MLSS
Proxy filing - Virtual meeting to vote on directors, share increases, equity plan, pay, and auditor ratification.MLSS
Proxy filing - Resale registration for 15.9M shares after $2.15M private placement; faces funding and compliance risks.MLSS
Registration filing - Q1 2026 saw stable revenue, sharply reduced losses, and improved liquidity amid ongoing risks.MLSS
Q1 2026 - Q3 2025 saw stable revenue, reduced costs, and improved net loss amid ongoing financial uncertainty.MLSS
Q3 2025